BSE FMCG Sector Regulatory Filings — October 23, 2026

Net sales up 12.2% YoY to Rs. 1,691.6 Crore and 6.3% QoQ, second consecutive quarter of double-digit domestic growth

PAT up only 4.3% YoY and down 0.4% QoQ to Rs. 341.6 Crore; ex-one-off PAT growth cited at 5.5%, signaling operating leverage is lagging volume growth

Rs. 24 per share First Interim Dividend declared for FY 2026-27 (record date Nov 2, payment Nov 19), maintaining shareholder payout visibility

PerioGard portfolio received the ISP Seal of Acceptance, the first such recognition in India, supporting premium oral-care positioning

Indonesian household insecticide plant (Kendal SEZ, Central Java) began commercial production October 23, 2026, adding export and in-market capacity for GCPI

Board meets October 30, 2026 to approve Q3 and nine-month results and declare a third interim dividend; trading window closed until November 1 limits pre-results insider signaling

Board meets November 5, 2026 for Q2 and H1 FY27 results; no pre-announced financial figures, so the signal set is limited to the scheduled event

Investor-meeting slate on November 16-18 at three Mumbai conferences with explicit no-UPSI commitment; a low-information event that confirms management engagement cadence

Sales rose 12.2% YoY while PAT rose only 4.3% and fell 0.4% QoQ, indicating cost or mix headwinds are compressing profitability relative to revenue growth

Reported PAT growth of 4.3% reflects one-off items; underlying growth of 5.5% is still well below sales growth, so headline earnings may overstate momentum

TDS on the Rs. 24 interim dividend ranges from Nil to 20% plus surcharge and cess for non-residents; documents are due to the RTA by November 2, 2026 at 5:00 PM IST and tax deducted is non-refundable, creating shareholder-level leakage risk

Results and a third interim dividend will be decided October 30 and the trading window is extended to November 1, so any earnings surprise will be unhedged by pre-results insider positioning and carries event risk for the stock

The Indonesian facility is only in first-phase commercial production with no disclosed capacity, cost, or revenue figures, leaving the payback and export-volume case unverified

Q2 and H1 FY27 results on November 5 were not previewed in the filing; investors have no disclosed guidance against which to judge the print

Results for Varun (Oct 30), Britannia (Nov 5) and the investor conference cluster (Nov 16-18) fall in a compressed window, raising the chance that multiple FMCG earnings and guidance changes land together and amplify sector-wide moves

6.3% QoQ sales growth against a second straight double-digit YoY quarter suggests volume-led share gains; a margin recovery in subsequent quarters would drive earnings upside

ISP Seal of Acceptance for PerioGard is a differentiated clinical-credential catalyst that can support pricing power in the periodontal segment

Rs. 24 interim dividend with a November 2 record date gives a near-term, pre-scheduled income event for holders, with payment on November 19

Indonesia facility commencing production on October 23 positions GCPI to serve domestic Indonesian demand and exports from a SEZ base, a scalable platform for regional insecticide growth

October 30 board meeting combines nine-month results with a third interim dividend declaration, a dual catalyst inside a single session

November 5 H1 FY27 results can serve as a read-through for mass-market packaged food demand, relevant given Colgate's concurrent growth in a different category

Three investor forums on November 16-18 provide a window for institutional engagement on portfolio and margin trajectory, with an explicit no-UPSI policy that keeps the interaction compliant and information-equal

Colgate's 12.2% YoY sales growth against 4.3% PAT growth illustrates a sector-wide tension where volume and pricing are holding up but input-cost, marketing, or mix pressures absorb margin; Varun and Britannia's upcoming results will test whether this is a single-company or sector pattern [IMPLICATION: monitor gross and EBITDA margins across the group in the next print cycle]

Board meetings for Varun (Oct 30) and Britannia (Nov 5) plus Colgate's interim dividend (record Nov 2, payment Nov 19) compress shareholder-return and information events into roughly three weeks, creating a concentrated catalyst window for FMCG large caps [IMPLICATION: expect elevated sector volatility and correlated repricing around these dates]

Varun's trading window closure extended to November 1 mirrors standard pre-results blackouts across the cohort, meaning insider transactions are unlikely to offer timing signals until post-results disclosures [IMPLICATION: insider-activity signals will be sparse for the next two weeks; rely on results-day guidance instead]

Godrej's Kendal SEZ insecticide plant reflects a broader theme of FMCG companies using export-oriented Special Economic Zone facilities in Southeast Asia to build scale and hedge domestic demand [IMPLICATION: track GCPI revenue contribution and whether peers announce comparable regional capacity]

The ISP Seal of Acceptance for Colgate's PerioGard signals that clinically endorsed claims are becoming a differentiator in oral care, with endorsement-based premiumization as a potential margin lever [IMPLICATION: credentialed sub-brands may command price premiums that offset broader margin pressure]

The detailed TDS treatment for Colgate's interim dividend, with rates from Nil to 20% and strict document deadlines, reflects increasing regulatory compliance burden on dividend recipients, particularly non-residents [IMPLICATION: investor-relations communications on dividend tax mechanics will become a routine, time-sensitive workload for FMCG issuers]

Board meeting October 30, 2026 to approve results and declare a third interim dividend; watch for margin trajectory and any dividend change against the trading-window extension to November 1

Board meeting November 5, 2026; watch for volume growth, gross margin, and whether management comments on input-cost or pricing trends that mirror Colgate's margin pressure

Documentation deadline to RTA on November 2, 2026 at 5:00 PM IST; record date November 2; payment November 19, 2026; watch for any change in the Rs. 24 dividend amount

Next quarterly print will show whether PAT growth re-accelerates toward sales growth; the 4.3% YoY PAT gap versus 12.2% sales growth is the key metric to track

Commercial production began October 23, 2026 in the Kendal SEZ; watch for capacity utilization, export volume disclosures, and any second-phase timing in subsequent filings

Meetings at CITIC CLSA (Nov 16), Avendus Spark (Nov 17), and JM Financial India Xchange (Nov 18) in Mumbai; watch for guidance tone, though the company has committed to no UPSI and the schedule is subject to change

Oct 30 to Nov 18 contains three board or investor events across the cohort; monitor for correlated sector moves and any commentary from one company that reads across to peers